Disruptive Nanotechonology Limited v. Elliot CA2/4

CourtCalifornia Court of Appeal
DecidedMarch 4, 2025
DocketB336941
StatusUnpublished

This text of Disruptive Nanotechonology Limited v. Elliot CA2/4 (Disruptive Nanotechonology Limited v. Elliot CA2/4) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Disruptive Nanotechonology Limited v. Elliot CA2/4, (Cal. Ct. App. 2025).

Opinion

Filed 3/4/25 Disruptive Nanotechonology Limited v. Elliot CA2/4 NOT TO BE PUBLISHED IN THE OFFICIAL REPORTS

California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION FOUR

DISRUPTIVE B336941 NANOTECHONOLOGY LIMITED, (Los Angeles County Plaintiff and Respondent, Super. Ct. No.23STCV19664)

v.

DANIEL ELLIOT et al.,

Defendants and Appellants.

APPEAL from an order of the Superior Court of Los Angeles County, Stuart M. Rice, Judge. Affirmed. Kendall, Brill & Kelly, Patrick J. Somers, Robert E. Dugdale, Daniel Barlava for Defendants and Appellants Innova Medical Group, Inc., Pasaca Capital, Inc., and Charles Huang; Kirkland & Ellis, Michael Shipley, Mark Holscher, David Horowitz, Matthew Gamsin, and Steven Czak for Defendant and Appellant Daniel Elliott; Brownstein Hyatt Farber Schreck, Jonathan C. Sandler for Defendant and Appellant Robert Kasprzak. Paul Hastings, Susan K. Leader, Ali R. Rabbani, Alyssa K. Tapper, and Will Ostrander for Plaintiff and Respondent.

INTRODUCTION Plaintiff Disruptive Nanotechnology, Ltd. (DNL) entered into two contracts with defendant Innova Medical Group, Inc. relating to the sale of Innova’s Covid-19 tests in the U.K. One contract was the Commission Agreement, under which DNL would get a commission for the sale of tests when DNL facilitated a sale between Innova and a buyer. The other contract was the Subdistribution Agreement, under which DNL would directly sell the product to buyers. DNL filed a complaint against Innova, its parent company Pasaca Capital, Inc., owner Charles Huang, and two principals at Innova, Daniel Elliott and Robert Kasprzak. DNL alleged that Innova breached the Commission Agreement by failing to pay certain commissions, and that the defendants fraudulently duped DNL into accepting decreased commissions so they could funnel to themselves commissions owed to DNL. DNL did not assert any claims under the Subdistribution Agreement. Defendants moved to compel arbitration. The Commission Agreement does not have an arbitration provision; it anticipates that disputes will be decided by courts in Los Angeles County. The Subdistribution Agreement contains an arbitration provision, and defendants contend arbitration is warranted under that provision, because even though none of DNL’s claims is based on the Subdistribution Agreement, defendants expect to rely on that agreement in their defense. The trial court denied

2 defendants’ motion to compel arbitration because DNL’s claims are based on the Commission Agreement, not the Subdistribution Agreement, and the parties did not consent to arbitrate disputes under the Commission Agreement. We agree and affirm. FACTUAL AND PROCEDURAL BACKGROUND A. Background1 DNL is a U.K. private limited company founded by Kimberley Thonger. At the beginning of the Covid-19 pandemic in early 2020, DNL “worked to facilitate the supply of individual COVID-19 tests and the provision of medical and nursing staff to its corporate customers (including business premises, travel hubs, and event spaces).” Innova is a California-based company that sells Covid-19 rapid antigen tests. It is a wholly owned subsidiary of Pasaca, a private equity firm. Huang founded Innova and Pasaca, and at various times served as chairman and chief financial officer of Pasaca and as chief executive officer of Innova. Elliott is a former president, chief executive officer, and director of Innova, and former president and director of Pasaca. Kasprzak is former in-house counsel, general counsel, chief legal officer, and director of Innova and Pasaca. In April 2020, Thonger was introduced to Elliott, who was then the president and CEO of Innova. Elliott asked if DNL would be interested in assisting Innova in navigating the U.K. procurement process and distributing Innova’s Covid-19 tests in the U.K. DNL agreed. DNL helped Innova apply to the U.K. Department of Health and Social Care (DHSC), then DNL managed the procurement process with the DHSC amid rapidly

1 The facts and quotes in this section are taken from the complaint unless otherwise noted.

3 changing standards and requirements. Approval for Innova’s initial antibody test was denied. DNL then applied for approval of a rapid antigen test Innova developed in the summer of 2020. DNL “work[ed] with Innova and the connections [DNL] had established within the DHSC to introduce the new antigen tests and explain the benefit they might provide in terms of mass testing.” The “process took many months and involved the shipment of thousands of samples to DNL, which DNL, in turn, ensured were ultimately delivered to government testing laboratories in the U.K.” In August 2020, DNL and Innova entered into two written agreements, both of which were drafted by Innova. The first was the “Commission Agreement,” under which DNL would facilitate the sale of Innova test kits in the U.K. in exchange for a commission on the sales. The Commission Agreement stated that DNL would “use its best efforts to assist in introducing [Innova] to Potential Buyers and facilitate, as needed, a sales transaction between [Innova] and the Potential Buyers.” Upon the completion of any such transaction, Innova would pay DNL “an amount per Product sold . . . equal to ten percent (10%) of [the] sales price of the Products paid by a Buyer.” According to the Commission Agreement, DNL would “not be purchasing or handling Products and shall therefore not be required to purchase, handle, pay for, or otherwise be engaged in purchases or handling (physically or otherwise) of Products. [DNL’s] role under this Agreement is confined to enabling [Innova] access to useful information and opportunities with Potential Buyers so that [Innova] may be able to sell, transport, and use Products.” The Commission Agreement did not have an arbitration clause. Rather, it stated that the contract was governed by

4 California law, and the “venue for any action brought hereunder shall be proper only in Los Angeles County, California, USA.” Language throughout the Commission Agreement anticipated that disputes would be addressed by a court. For example, it stated that in the event of a breach involving the confidentiality provisions, “the non-breaching Party shall have the right and remedy to have the provisions of this Article 4 specifically enforced by any court having equity jurisdiction and/or the right to obtain injunctive relief.” The severability provision anticipated that a portion of the contract could be deemed illegal or unenforceable “by any court of competent jurisdiction.” The Commission Agreement also stated, “5.06. Court Costs and Attorneys’ Fees. If any action at law or in equity, including an action for declaratory relief, is brought to enforce or interpret the provisions of this Agreement, the prevailing party shall be entitled to recover costs of court and reasonable attorneys’ fees from the other party or parties to such action, which fees may be set by the court in the trial of such action or may be enforced in a separate action brought for that purpose, and which fees shall be in addition to any other relief that may be awarded.” The Commission Agreement had an integration clause stating, “This Agreement contains the entire understanding between the parties hereto concerning the subject matter contained herein.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Christopher L. Gore v. Alltel Commu
666 F.3d 1027 (Seventh Circuit, 2012)
Pinnacle Museum Tower Ass'n v. Pinnacle Market Development (US), LLC
282 P.3d 1217 (California Supreme Court, 2012)
Nestle Waters North America, Inc. v. Bollman
505 F.3d 498 (Sixth Circuit, 2007)
Cardiff Equities, Inc. v. Superior Court
166 Cal. App. 4th 1541 (California Court of Appeal, 2008)
Thompson v. Toll Dublin, LLC
165 Cal. App. 4th 1360 (California Court of Appeal, 2008)
Hayter Trucking, Inc. v. Shell Western E & P, Inc.
18 Cal. App. 4th 1 (California Court of Appeal, 1993)
Williams v. Atria Las Posas
235 Cal. Rptr. 3d 341 (California Court of Appeals, 5th District, 2018)
Kevin Johnson v. Walmart Inc.
57 F.4th 677 (Ninth Circuit, 2023)
Kevin Sapp v. Industrial Action Services LLC
75 F.4th 205 (Third Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Disruptive Nanotechonology Limited v. Elliot CA2/4, Counsel Stack Legal Research, https://law.counselstack.com/opinion/disruptive-nanotechonology-limited-v-elliot-ca24-calctapp-2025.